Immutep presents positive IMP761 preclinical results

8 March 2019 |

Immutep today announced positive results from its preclinical study of IMP761, a novel LAG3 agonist antibody being developed for the treatment of autoimmune diseases. The results were presented at the 14th Congress of European Crohn’s and Colitis Organisation (ECCO) Conference in Denmark.

Consistent with earlier in vitro studies conducted by Immutep on the immunosuppressive activity of IMP761, this new study in a non-human primate animal model showed that IMP761 decreases inflammatory T cell infiltration induced by intra-dermal injection of an antigen.

Read the full press release

Category: Member News

Home

News & opinion

Member Directory

Events

CLICK HERE TO SUBSCRIBE TO OUR NEWSLETTER

BioMelbourne Network respectfully acknowledges the Traditional Custodians of the unceded lands and waters of Victoria, the Bunurong, Eastern Maar, Gunaikurnai, Wadawurrung and Wurundjeri Woi-wurrung peoples, on which BioMelbourne Network lives and works. We pay respect to their Elders past and present. We acknowledge the significant contribution that they and other Aboriginal and Torres Strait Islander people have made and continue to make to the research and knowledge systems that inform our community and our sector.

We acknowledge that Aboriginal and Torres Strait Islander people continue to live in a spiritual and sacred relationship with this country and recognise our responsibility to continue to work towards reconciliation.